Literature DB >> 16676065

A potent anti-coagulant RNA aptamer inhibits blood coagulation by specifically blocking the extrinsic clotting pathway.

Subash C B Gopinath1, Yasuo Shikamoto, Hiroshi Mizuno, Penmetcha K R Kumar.   

Abstract

A potent antidote-controlled aptamer, as an anticoagulant, has reportedly overcome the complications of acute bleeding by the administration of available anticoagulants. In the present study, we provide evidence that the aptamer binds specifically to factors IX and IXa and inhibits their functions. Furthermore, we demonstrated that the aptamer inhibits blood coagulation by interfering with the extrinsic pathway, blocking the complex of factor VIIa and tissue factor interactions with factor IX. The results from the previous and present studies suggest that the aptamer probably binds in the vicinity of the EGF1 and EGF2 domains of factor IX.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16676065

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  11 in total

1.  Dose selection for a direct and selective factor IXa inhibitor and its complementary reversal agent: translating pharmacokinetic and pharmacodynamic properties of the REG1 system to clinical trial design.

Authors:  T J Povsic; M G Cohen; M Y Chan; S L Zelenkofske; W A Wargin; R A Harrington; J H Alexander; C P Rusconi; R C Becker
Journal:  J Thromb Thrombolysis       Date:  2011-07       Impact factor: 2.300

2.  Potent anticoagulant aptamer directed against factor IXa blocks macromolecular substrate interaction.

Authors:  Bruce Sullenger; Rebecca Woodruff; Dougald M Monroe
Journal:  J Biol Chem       Date:  2012-02-13       Impact factor: 5.157

3.  Snake-venom-derived Factor IX-binding protein specifically blocks the gamma-carboxyglutamic acid-rich-domain-mediated membrane binding of human Factors IX and X.

Authors:  Subash C B Gopinath; Yasuo Shikamoto; Hiroshi Mizuno; Penmetcha K R Kumar
Journal:  Biochem J       Date:  2007-07-15       Impact factor: 3.857

Review 4.  Factor IX(a) inhibitors: an updated patent review (2003-present).

Authors:  Daniel K Afosah; Edward Ofori; Madhusoodanan Mottamal; Rami A Al-Horani
Journal:  Expert Opin Ther Pat       Date:  2022-01-17       Impact factor: 6.674

Review 5.  Translation and Clinical Development of Antithrombotic Aptamers.

Authors:  Shahid M Nimjee; Thomas J Povsic; Bruce A Sullenger; Richard C Becker
Journal:  Nucleic Acid Ther       Date:  2016-02-16       Impact factor: 5.486

6.  Alzheimer's Disease Determination by a Dual Probe on Gold Nanourchins and Nanohorn Hybrids.

Authors:  Zhengguo Qiu; Qianhe Shen; Chao Jiang; Li Yao; Xiaopeng Sun; Jing Li; Chongzhen Duan; Rui Li; Xiuli Li; Subash C B Gopinath; Periasamy Anbu; Thangavel Lakshmipriya; Xu Li
Journal:  Int J Nanomedicine       Date:  2021-03-19

7.  Anticoagulant and Antiplatelet Activities of Artemisia princeps Pampanini and Its Bioactive Components.

Authors:  Ri Ryu; Un Ju Jung; Hye-Jin Kim; Wonhwa Lee; Jong-Sup Bae; Yong Bok Park; Myung-Sook Choi
Journal:  Prev Nutr Food Sci       Date:  2013-09

8.  Evaluation of antithrombotic activity of thrombin DNA aptamers by a murine thrombosis model.

Authors:  Elena Zavyalova; Nadezhda Samoylenkova; Alexander Revishchin; Andrey Golovin; Galina Pavlova; Alexey Kopylov
Journal:  PLoS One       Date:  2014-09-05       Impact factor: 3.240

9.  Red Spectral Shift in Sensitive Colorimetric Detection of Tuberculosis by ESAT-6 Antigen-Antibody Complex: a New Strategy with Gold Nanoparticle.

Authors:  Fu-An Wang; Thangavel Lakshmipriya; Subash C B Gopinath
Journal:  Nanoscale Res Lett       Date:  2018-10-23       Impact factor: 4.703

Review 10.  Recent Advances in Identifying Biomarkers and High-Affinity Aptamers for Gynecologic Cancers Diagnosis and Therapy.

Authors:  Xiaoqun Ma; Thangavel Lakshmipriya; Subash C B Gopinath
Journal:  J Anal Methods Chem       Date:  2019-09-08       Impact factor: 2.193

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.